NEW YORK (GenomeWeb News) - Ambit Biosciences has expanded an agreement with Bristol-Myers Squibb for kinase discovery research, Ambit said today.
Under the agreement, Ambit will use its KinomeScan method to screen small-molecule libraries against "a large number of human kinases," Ambit said, continuing a relationship begun in 2004.
Ambit's KinomeScan uses binding assays to determine how compounds bind to intended and unintended kinases, the company said.
The agreement calls for Bristol Myers-Squibb to give Ambit an undisclosed cash payment on the front end, and Ambit will retain the rights to certain of Bristol Myers-Squibb's preclinical and clinical compounds.